The aim of the Clinical Adherence Core will be to enhance patient recruitment and maintain adherence to the chemoprevention regimen in the clinical studies (Projects 1, 2, and 3). The Adherence Core will use behavioral science strategies to enhance compliance of all enrolled patients and to identify and intervene with patients who may have special adherence problems. The strategies will include brief counseling, patient education materials and a newsletter. These strategies will address relevant behavioral variables such as perceived susceptibility, perceived seriousness, benefits of the intervention and reduction of barriers, self efficacy and altruism. The Core will train Adherence Coordinators in each of the RTOG and CCOP clinical research locations (Projects 1,2) and maintain frequent Core coordination and monitoring of recruitment and adherence. In Project 3, at M.D. Anderson, special clinical interviewing and counseling for leukoplakia patients will be provided to enhance adherence. In addition to enhancement of adherence, the Core will study differences between adherents and non-adherents. A six-factor heuristic model, developed by Gritz, et al. at the Jonsson Cancer Center, for describing the variables affecting adherence with cancer control regimens, will be used as a framework. Selected scales for measuring behavioral variables will be adapted from work by Atwood, et al. from the Colon Cancer Prevention Project at the Arizona Cancer Center. A discriminant analysis of the variables in the six-factor model will be used to develop a model of adherence for chemoprevention trials in aerodigestive cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
3P01CA052051-05S1
Application #
5207643
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
1996
Total Cost
Indirect Cost
Hildebrandt, Michelle A T; Lippman, Scott M; Etzel, Carol J et al. (2012) Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention. Clin Cancer Res 18:3705-13
Lee, J Jack; Wu, Xifeng; Hildebrandt, Michelle A T et al. (2011) Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res (Phila) 4:185-93
Wang, Jianming; Lippman, Scott M; Lee, J Jack et al. (2010) Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurrence in head and neck squamous cell carcinoma. Carcinogenesis 31:1755-61
Zhang, Xiaofan; Yang, Hushan; Lee, J Jack et al. (2010) MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer. Carcinogenesis 31:2118-23
William Jr, William N; Lee, J Jack; Lippman, Scott M et al. (2009) High-dose fenretinide in oral leukoplakia. Cancer Prev Res (Phila) 2:22-6
Papadimitrakopoulou, Vassiliki A; Lee, J Jack; William Jr, William N et al. (2009) Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol 27:599-604
Wu, Xifeng; Spitz, Margaret R; Lee, J Jack et al. (2009) Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res (Phila) 2:617-24
Kawaguchi, Hidetoshi; El-Naggar, Adel K; Papadimitrakopoulou, Vali et al. (2008) Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 26:354-60
Wu, Xifeng; Gu, Jian; Dong, Qiong et al. (2006) Joint effect of mutagen sensitivity and insulin-like growth factors in predicting the risk of developing secondary primary tumors and tumor recurrence in patients with head and neck cancer. Clin Cancer Res 12:7194-201
Lippman, Scott M; Lee, J Jack (2006) Reducing the ""risk"" of chemoprevention: defining and targeting high risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture. Cancer Res 66:2893-903

Showing the most recent 10 out of 91 publications